Study points out that HIV vaccine may not be accepted easily
Researchers feel that in the next ten years, the HIV vaccine will be ready for use, but there may// be a lot of barriers preventing the acceptance of the vaccine by the people. The research done by University of Toronto researchers said that it is important that the health workers of the world gets the common people ready for accepting the vaccine, which may be quite difficult job to d...Maverick Gay Ex-governor Turns a New Leaf - Accepted at the Episcopalian Seminary
New Jersey –The nation’s publicized gay governor, James E. McGreevy appears to be knocking on a different door. This time he has managed to be in the news// for the right reasons. He has been welcomed into the seminary and has become an Episcopalian. Former Gov. James E. McGreevy, who was brought up as a Roman Catholic, was officially inducted into the Episcopal religion on Sunday at S...Maverick Gay Ex-governor Turns a New Leaf - Accepted at the Episcopalian Seminary
New Jersey The nations publicized gay governor, James E. McGreevy appears to be knocking on a different door. This time he has managed to be in the news for the right reasons. He has been welcomed into the seminary and has become an Episcopalian. Former Gov. James E. McGreevy, who was brought up as a Roman Catholic, was officially inducted into the Episcopal religion on Sunday at St...Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
- Phase I data from XL880, Phase II data from XL999 studiesscheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --Exelixis, Inc. announced today that data from clinical trials ofthe company's investigational compounds XL880 and XL999 will bepresented at the 2007 American Society of Clinical Oncology AnnualMeeting (ASCO), which...SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
SAN MATEO, CA — April 27, 2007 — SciClonePharmaceuticals, Inc. (NASDAQ: SCLN) today announced that thefollowing abstracts have been accepted for the Annual Meeting ofthe American Society of Clinical Oncology in Chicago, Illinois onJune 1-5, 2007: ZADAXIN® (thymalfasin, thymosin alpha 1) PosterPresentation A large first-line, randomized, dose-finding, ph...